PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that regulate lipid and glucose metabolism and cellular differentiation. PPAR-alpha and PPAR-gamma are both expressed in human macrophages where they exert anti-inflammatory effects. The activation of PPAR-alpha may promote foam-cell formation by inducing expression of the macrophage scavenger receptor CD36. This prompted us to investigate the influence of different PPAR-activators on cholesterol metabolism and foam-cell formation of human primary and THP-1 macrophages. Here we show that PPAR-alpha and PPAR-gamma activators do not influence acetylated low density lipoprotein-induced foam-cell formation of human macrophages. In contrast, PPAR-alpha and PPAR-gamma activators induce the expression of the gene encoding ABCA1, a transporter that controls apoAI-mediated cholesterol efflux from macrophages. These effects are likely due to enhanced expression of liver-x-receptor alpha, an oxysterol-activated nuclear receptor which induces ABCA1-promoter transcription. Moreover, PPAR-alpha and PPAR-gamma activators increase apoAI-induced cholesterol efflux from normal macrophages. In contrast, PPAR-alpha or PPAR-gamma activation does not influence cholesterol efflux from macrophages isolated from patients with Tangier disease, which is due to a genetic defect in ABCA1. Here we identify a regulatory role for PPAR-alpha and PPAR-gamma in the first steps of the reverse-cholesterol-transport pathway through the activation of ABCA1-mediated cholesterol efflux in human macrophages.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This mechanism is pivotal in controlling intracellular lipid content and serves as a primary “gatekeeper” for reverse cholesterol transport in cells [23].”
From miR-223 accelerates lipid droplets clearance in microglia following spinal cord injury by upregulating ABCA1 (2024) · cites this paper as [23]
In the citing paper
“The activation of PPARα also accelerates reverse cholesterol transport (RCT) via increased expression of ABCA1 and ABCG1 transporters involved in cholesterol efflux from macrophages [29, 40].”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [40]
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
The pathogenesis of atherosclerosis: a perspective for the 1990s
Ross, R. (1993) · Nature · doi:10.1038/362801a0 · Cited by 10,630 · cited 1×
“, and this led to the suggestion that PPAR-activators may modulate foam-cell formation, a known atherogenic process characterized by cholesteryl-ester-droplet accumulation in the cytoplasm of macrophage”
BackgroundThe peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899 · cited 1×
“Both PPAR-α and PPAR-γ are expressed in fully-differentiated human macrophages where they regulate genes implicated in the inflammatory response, modulate macrophage differentiation and promote TNF-α/IFN-γ–induced apoptosi”
BackgroundThe PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816 · cited 1×
“We treated these cells with either the PPAR-α ligand Wy14643 or the PPAR-γ ligand rosiglitazone at concentrations of 2–3 times their EC 50 values (Wy14643 EC 50 for human PPAR-αe25 μM and rosiglitazone EC 50 for human PPAR-γe43 nM”
PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL
Tontonoz, P., Nagy, L., Alvarez, J. G. A., Thomazy, V. A., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81575-5 · Cited by 1,797 · cited 1×
“Moreover, PPAR-α activation results in the transcriptional induction of CD36 expression in macrophage”
BackgroundMechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786 · cited 1×
“The stimulatory role of PPAR-α activators on hepatic HDL production and apoAI expression is well-documente”
BackgroundSelf-citationMutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency
Brooks-Wilson, A., Marcil, M., Clee, S. M., Zhang, L.-H., Roomp, K., van Dam, M., Yu, L., Brewer, C., Collins, J. A., Molhuizen, H. O. F., et al. (1999) · Nature Genetics · doi:10.1038/11905 · Cited by 1,687
An oxysterol signalling pathway mediated by the nuclear receptor LXRα
Janowski, B. A., Willy, P. J., Devi, T. R., Falck, J. R., & Mangelsdorf, D. J. (1996) · Nature · doi:10.1038/383728a0 · Cited by 1,591 · cited 1×
“We also show that both PPAR-α and PPAR-γ activators induce ABCA1 expression, possibly through their inductive effects on expression of LXR-α, a nuclear receptor activated by oxysterol”
Background
Cited by
Items 801–900 of 1,000
Silva, A. K. S. E., Torres, D. D. O. C., Rocha, S. W. S., Gomes, F. O. D. S., Silva, B. D. S., Donato, M. A. M., Rapôso, C., dos Santos, A. C. O., de Lima, M. D. C. A., Galdino, S. L., et al. (2012) · Cardiovascular Pathology · doi:10.1016/j.carpath.2012.05.006 · Cited by 16
Yongsakulchai, P., Settasatian, C., Settasatian, N., Komanasin, N., Kukongviriyapan, U., Coté, M. L., Intharapetch, P., & Senthong, V. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.03.005 · Cited by 14
Wang, L., Palme, V., Schilcher, N., Ladurner, A., Heiß, E. H., Stangl, H., Bauer, R., Dirsch, V. M., & Atanasov, A. G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00596 · Cited by 13
“Thus, the activation of the ligand-dependent nuclear receptors peroxisome proliferator-activated receptor gamma (PPARγ) and subsequently the liver X receptor (LXR), can lead to increased ABCA1 gene transcription (Chawla et al., 2001; Chinetti et al., 2001; Ozasa et al., 2011).”
BackgroundMethodResultInfluentialGliozzi, M., Macrì, R., Coppoletta, A. R., Musolino, V., Carresi, C., Scicchitano, M., Bosco, F., Guarnieri, L., Cardamone, A., Ruga, S., et al. (2022) · Nutrients · doi:10.3390/nu14183737 · Cited by 14
He, Y., Zhang, L., Li, Z., Gao, H., Yue, Z., Liu, Z., Liu, X., Feng, X., & Liu, P. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.01.001 · Cited by 14
Pharmacological evidence for a role of liver X receptors in atheroprotection
Kovanen, P. T., & Pentikäinen, M. O. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00011-5 · Cited by 13
Tremblay, A. J., Lamarche, B., Ruel, I. L., Hogue, J., Deshaies, Y., Gagné, C., & Couture, P. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.10.037 · Cited by 15
Influence of conjugated linoleic acids on functional properties of vascular cells
Ringseis, R., & Eder, K. (2009) · British Journal Of Nutrition · doi:10.1017/s0007114509990304 · Cited by 18
Synthetic Statins: More Data on Newer Lipid-lowering Agents
Wierzbicki, A. S. (2001) · Current Medical Research and Opinion · doi:10.1185/03007990152005388 · Cited by 13
Impact of thiazolidinedione therapy on atherogenesis
van Wijk, J. P. H., & Rabelink, T. J. (2005) · Current Atherosclerosis Reports · doi:10.1007/s11883-005-0049-6 · Cited by 13
Importance of blood cellular genomic profile in coronary heart disease
Baba, M. I., Kaul, D., & Grover, A. (2005) · Journal of Biomedical Science · doi:10.1007/s11373-005-9041-y · Cited by 14
“These observations are in conformity with the transcriptional regulatory pathways that exist between the genes coding for PPARs (a, c) and LXRa [24].”
ResultGoacutemez-Peacuterez, F. J., Aguilar-Salinas, C. A., V[aacute]zquez-Ch[aacute]vez, C., nel-Salmoacuten, G. F., Gallegos-Mart[iacute]nez, J., Goacutemez-Diaz, R. A., Orozco, S. S., Chavira-Loacutepez, I. J., Saacutenchez-Reyes, L., Torres-Acosta, E. M., et al. (2002) · Metabolism · doi:10.1053/meta.2002.29024 · Cited by 13
Gellrich, L., & Merk, D. (2017) · Nuclear Receptor Research · doi:10.11131/2017/101310 · Cited by 15
Rao, M. S., McDuffie, E., Srivastava, S., Plaisted, W. C., & Sachs, C. W. (2024) · Pharmaceuticals · doi:10.3390/ph17070875 · Cited by 13
Yin, Q.-X., Chang, H., Shen, Q., & Xing, D. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16531 · Cited by 14
Hana, C. A., Tran, L. V., Mölzer, C., Müllner, E., Hörmann-Wallner, M., Franzke, B., Tosevska, A., Zöhrer, P. A., Doberer, D., Marculescu, R., et al. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154913 · Cited by 14
Toth, P. P. (2010) · Current Cardiology Reports · doi:10.1007/s11886-010-0136-3 · Cited by 12
PPARα: its role in the human metabolic syndrome
Azhar, S., & Kelley, G. (2007) · Future Lipidology · doi:10.2217/17460875.2.1.31 · Cited by 14
“• RCT (LXRα and ABCA1 [216,218]);”
Xu, G., Yang, L., Guan, P.-P., Wang, Z., & Wang, P. (2019) · Neurotherapeutics · doi:10.1007/s13311-018-00704-1 · Cited by 12
Lipid-Modifying Drugs: Pharmacology and Perspectives
Xu, R.-X., & Wu, Y. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-2517-9_5 · Cited by 12
Inaba, T., Yagyu, H., Itabashi, N., Tazoe, F., Fujita, N., Nagashima, S., Okada, K., Okazaki, M., Furukawa, Y., & Ishibashi, S. (2008) · Hypertension Research · doi:10.1291/hypres.31.999 · Cited by 14
Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?
Brinton, E. A. (2008) · Current Atherosclerosis Reports · doi:10.1007/s11883-008-0005-3 · Cited by 13
Pascual, G., Ricote, M., & Hevener, A. L. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.11.1503 · Cited by 12
“LIANG CP, HAN S, OKAMOTO H et al. : Increased CD36 protein as a response to defective insulin signaling in macrophages.”
BackgroundEndo, Y., Sasaki, K., & Ikewaki, K. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22042 · Cited by 17
Liu, H., Li, Y., Yan, J., Li, X., Wang, D., Yu, X., Jiang, Z., Yin, G., Chen, S., Zhang, X., et al. (2024) · Phytotherapy Research · doi:10.1002/ptr.8182 · Cited by 14
“…2011). peroxisome proliferator-activated receptors (PPARs) (Cho et al., 2011; Goldwasser et al., 2010); which increase plasma HDL levels, improve insulin sensitivity, and decrease adiposity, among others, thereby playing an atheroprotective role (Chinetti et al., 2001; Guerre-Millo et al., 2000).”
Macrophage polarization as a novel endpoint for assessing combined risk of phthalate esters
Wang, X., Xu, M., Shi, M., Tian, Y., Zhi, Y., Han, X., Sui, H., Wan, Y., Jia, X., & Yang, H. (2024) · Environment International · doi:10.1016/j.envint.2024.108835 · Cited by 12
Xu, X., Chen, Q., Li, S., & Xiong, T. (2025) · NeuroMarkers. · doi:10.1016/j.neumar.2024.100035 · Cited by 12
Abaj, F., Sotoudeh, G., Karimi, E., Rafiee, M., & Koohdani, F. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14307 · Cited by 11
Cammarota, M., Ferlenghi, F., Vacondio, F., Vincenzi, F., Varani, K., Bedini, A., Rivara, S., Mor, M., & Boscia, F. (2022) · British Journal of Pharmacology · doi:10.1111/bph.16014 · Cited by 12
“PPARα is a ligand-dependent transcription factor that mediates the trans-repression of the main inflammatory transcription factors and acts as a master regulator of lipid metabolism and cholesterol homeostasis (Chinetti et al., 2001).”
BackgroundHärdtner, C., Kumar, A., Ehlert, C. A., Vico, T. A., Starz, C., von Ehr, A., Krebs, K., Dufner, B., Hoppe, N., Stachon, P., et al. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.03.006 · Cited by 12
Fibrates and coronary heart disease reduction in diabetes
Robins, S. J. (2002) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/00060793-200208000-00004 · Cited by 11
Fumigaclavine C activates PPARγ pathway and attenuates atherogenesis in ApoE-deficient mice
Du, R. H., Qin, S. Y., Shi, L., Zhou, Z. Q., Zhu, X., Liu, J., Tan, R. X., & Cao, W. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.02.016 · Cited by 12
Johnston, T. P., & Waxman, D. J. (2008) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y08-070 · Cited by 11
“2006), which is opposite to the action of both PPARa and PPARg agonists (Chawla et al. 2001; Chinetti et al. 2001), perhaps cholesterol homeostasis is maintained, in part, by a P-407-mediated release of FFAs (an essential substrate for both TG and cholesterol synthesis) from adipocytes, as well as by an increase in ch…”
HDL as a prognostic biomarker for coronary atherosclerosis: the role of inflammation
Παπαγεωργίου, Ν., Zacharia, E. M., Androulakis, E. S., Briasoulis, Α., Charakida, M., & Tousoulis, D. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1152264 · Cited by 14
Holen, E., He, J.-Y., Araujo, P., Seliussen, J., & Espe, M. (2016) · Fish and Shellfish Immunology · doi:10.1016/j.fsi.2016.03.030 · Cited by 12
Role of Leptin in Acute Ischemic Stroke
Menon, B., & Ramalingam, K. (2018) · Journal of Neurosciences in Rural Practice · doi:10.4103/jnrp.jnrp_5_18 · Cited by 11
Quantifying Cellular Cholesterol Efflux
Robichaud, S., & Ouimet, M. I. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9130-3_9 · Cited by 11
Liang, L., Xie, Q., Sun, C., Wu, Y., Zhang, W., & Li, W. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03151-3 · Cited by 12
“It has been confirmed that, in macrophages, PPAR-γ and LXR-α controlled the cholesterol removal through the modulation of ABCA1 [25].”
BackgroundNovel Therapies for Increasing Serum Levels of HDL
Toth, P. P. (2009) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.11.012 · Cited by 12
Fenofibrate in the treatment of dyslipidemia associated with HIV infection
Samineni, D., & Fichtenbaum, C. J. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.504715 · Cited by 11
Lipid‐activated nuclear receptors: from gene transcription to the control of cellular metabolism
Crestani, M., Mitro, N., & Fabiani, E. D. (2004) · European Journal of Lipid Science and Technology · doi:10.1002/ejlt.200300936 · Cited by 12
Atherosclerosis and cardiovascular risk reduction with PPAR agonists
Kuusisto, J., Andrulionytė, L., & Laakso, M. (2007) · Current Atherosclerosis Reports · doi:10.1007/s11883-007-0033-4 · Cited by 11
Hwang, K., Hwang, Y.-J., & Song, J. (2017) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2017.06.007 · Cited by 14
Novel agents for managing dyslipidaemia
Jenkins, A. J., & Best, J. D. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.11.1901 · Cited by 11
The significance of genetic polymorphisms in modulating the response to lipid-lowering drugs
Hoffmann, M. M., Winkelmann, B. R., Wieland, H., & März, W. (2001) · Pharmacogenomics · doi:10.1517/14622416.2.2.107 · Cited by 13
Lie, J. T., Lankhuizen, I. M., Gross, B. S., vanGent, T., VANHAPEREN, R., Scheek, L. M., Staels, B., DECROM, R., & Vantol, A. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2005.10.002 · Cited by 12
Self-citationChromogranin A and its derived peptides: potential regulators of cholesterol homeostasis
Iyer, D. R., Venkatraman, J., Tanguy, É., Vitale, N., & Mahapatra, N. R. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04908-3 · Cited by 11
Wang, Y., Chen, Y., Chen, S., Chen, X., Chen, J., Shen, X., Mou, Y., & Liu, P. (2010) · Pharmacology · doi:10.1159/000321727 · Cited by 10
Genetic variants in ABCA1 promoter affect transcription activity and plasma HDL level in pigs
Dang, X., Chu, W., Shi, H.-C., Yu, S., Han, H., Gu, S., & Chen, J. (2014) · Gene · doi:10.1016/j.gene.2014.11.041 · Cited by 11
“Peroxisome proliferator-activated receptor α (PPARα) and PPARγ activators may also enhance the activity of ABCA1 expression (Chawla et al., 2001; Chinetti et al., 2001; Ruan et al., 2003).”
BackgroundThe beneficial effects of HDL-C on atherosclerosis: rationale and clinical results
Santos‐Gallego, C. G., Torres, F., & Badimón, J. J. (2011) · Clinical Lipidology · doi:10.2217/clp.10.90 · Cited by 11
Li, J., Xiu, Z., Wang, R., Yu, C., Yan, C., Qin, J., Fu, C., Matsuura, E., & Liu, Q. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.03.024 · Cited by 10
Engineering Mammalian Designer Cells for the Treatment of Metabolic Diseases
Wang, Y., Wang, M., Dong, K., & Ye, H. (2017) · Biotechnology Journal · doi:10.1002/biot.201700160 · Cited by 11
Sini decoction intervention on atherosclerosis via PPARγ-LXRα-ABCA1 pathway in rabbits
Ju, S., Chang, X.-R., Wang, J., Zou, X., Zhao, Z., Huang, Z., Wang, Y., & Yu, B. (2018) · Open Life Sciences · doi:10.1515/biol-2018-0053 · Cited by 10
Steiner, G. A. (2005) · Treatments in Endocrinology · doi:10.2165/00024677-200504050-00004 · Cited by 10
Rosenblat, M., Volkova, N., Khatib, S., Mahmood, S., Vaya, J., & Aviram, M. (2014) · Free Radical Research · doi:10.3109/10715762.2014.963574 · Cited by 10
“In this regard, the nuclear factor PPARα was shown to induce the expression of ABCA1 in macrophages through a transcriptional cascade mediated by the nuclear receptor LXR [33].”
BackgroundSharma, S., Sowjanya, A., Kumari, M., Raichur, S., Gershome, C., Suresh, J., & Chakrabarti, R. (2006) · Life Sciences · doi:10.1016/j.lfs.2006.09.009 · Cited by 11
Cholesterol attenuates linoleic acid-induced endothelial cell activation
Meerarani, P., Smart, E. J., Toborek, M. J., Boissonneault, G. A., & Hennig, B. (2003) · Metabolism · doi:10.1053/meta.2003.50087 · Cited by 11
Discovering Functional Modules by Topic Modeling RNA-Seq Based Toxicogenomic Data
Yu, K., Gong, B., Lee, M., Liu, Z., Xu, J., Perkins, R., & Tong, W. (2014) · Chemical Research in Toxicology · doi:10.1021/tx500148n · Cited by 10
Current practice in the treatment of hyperlipidaemias
Duriez, P. (2001) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2.11.1777 · Cited by 10
HDL: The ‘new’ target of cardiovascular medicine
Sampietro, T., Bigazzi, F., Pino, B. D., Puntoni, M., & Bionda, A. (2005) · International Journal of Cardiology · doi:10.1016/j.ijcard.2005.04.036 · Cited by 10
Ruel, I. L., Lamarche, B., Mauger, J., Badellino, K. O., Cohn, J. S., Marcil, M., & Couture, P. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000190700.76493.bb · Cited by 11
Bellosta, S., Bernini, F., Chinetti, G., Cignarella, A., Cullen, P., von Eckardstein, A., Exley, A., Freeth, J. S., Goddard, M. J., Hofker, M. H., et al. (2002) · PubMed · Cited by 11
Self-citationRole of PPARγ in dyslipidemia and altered pulmonary functioning in mice following ozone exposure
Smith, L. C., Gow, A. J., Абрамова, Е. В., Vayas, K. N., Guo, C., Noto, J., Lyman, J., Rodriquez, J., Gelfand-Titiyevskiy, B., Malcolm, C., et al. (2023) · Toxicological Sciences · doi:10.1093/toxsci/kfad048 · Cited by 9
Wu, H., Mi, Y., Zheng, C., Zhang, Y., Xu, S., Zhu, J., & Jin, T. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107179 · Cited by 9
Zhang, H., Li, C., Xin, Y., Cui, X., Cui, J., & Zhou, G. (2020) · Bioscience Biotechnology and Biochemistry · doi:10.1080/09168451.2020.1719823 · Cited by 8
“This cross-talk had also been observed in macrophages [16,17].”
BackgroundHigh-density lipoprotein-based drug discovery for treatment of atherosclerosis
Du, Y., Wang, L., & Hong, B. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1051963 · Cited by 9
Nuclear receptors in abdominal aortic aneurysms
Neels, J. G., Hassen‐Khodja, R., & Chinetti, G. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.02.009 · Cited by 9
Self-citationLee, D.-H., Choi, S.-S., Kim, B.-B., Kim, S. Y., Kang, B.-S., Lee, S., & Park, H. (2013) · Process Biochemistry · doi:10.1016/j.procbio.2013.09.007 · Cited by 9
A novel enzyme immunoassay specific for ABCA1 protein quantification in human tissues and cells
Paul, V., Meyer, H. H. D., Leidl, K., Soumian, S., & Albrecht, C. (2008) · Journal of Lipid Research · doi:10.1194/jlr.d700040-jlr200 · Cited by 9
Peroxisome proliferator-activated receptor ligands in atherosclerosis
Viles-González, J. F., Choi, B. G., Fuster, V., & Badimón, J. J. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.11.1393 · Cited by 9
“other dual agonists are being developed including ureido fibrates that have potent cholesterol and triglyceride lowering activity [51,52].”
BackgroundHIV-associated lipodystrophy: Description, pathogenesis, and molecular pathways
Mallon, P. W. G., Carr, A. D., & Cooper, D. A. (2002) · Current Diabetes Reports · doi:10.1007/s11892-002-0070-x · Cited by 10
Strobach, D., & Lorenz, R. L. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)01127-6 · Cited by 9
Therapeutical effects of PPAR agonists assessed by biomarker modulation
Chinetti, G., Fruchart, J., & Staels, B. (2005) · Biomarkers · doi:10.1080/13547500500216702 · Cited by 11
“Nevertheless, PPARg ligands clearly inhibit TNFa, IL-6 and IL-1b expression in monocytes, IFNg-induced expression of the T-cell-specific CXC-chemokines, IFNginducible protein 10 (IP-10), Mig, I-TAC and cell-adhesion molecules and endothelin-1 in endothelial cells (Chinetti et al. 2001b).”
BackgroundSelf-citationAn Updated Review of its Clinical Efficacy in the Management of Dyslipidaemia
Drury, P., Franceschini, G., Malík, J., Melenovský, V., & Pasceri, V. (2002) · Cited by 9
Rival, Y., Puech, L., Taillandier, T., Benéteau, N., Rouquette, A., Lestienne, F., Dupont-Passelaigue, E., Roy, I. L., Patoiseau, J., & Junquero, D. C. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.01.010 · Cited by 9
Lipid-laden macrophages in atherosclerosis and cancer
Martínez-Campanario, M. C., Cortés, M., Han, L., Brischetto, A., Rivero-Soriano, P., Font-Díaz, J., Maurel, J., Andrés, V., & Postigo, A. A. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.09.007 · Cited by 10
Sclerochorioretinal Abnormalities in Hypercholesterolemic Rabbits Treated with Rosiglitazone
Torres, R. J. D. A., Muccioli, C., Maia, M., de Noronha, L., Luchini, A., Alessi, A., Olandoski, M., Farah, M. E., & Précoma, D. B. (2010) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/15428877-20100726-05 · Cited by 6
A review of paradoxical HDL-C responses to fenofibrate, illustrated by a case report.
Schofield, J., Liu, Y.-F., France, M., Sandle, L., & Soran, H. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.05.003 · Cited by 6
Regulation of Cholesterol Transporters by Nuclear Receptors
Matsuo, M. (2023) · Receptors · doi:10.3390/receptors2040014 · Cited by 9
“Agonists for PPAR α and PPAR γ also induce the expression of ABCA1 and ABCG1 via LXR [56–58].”
Li, X., Li, Y., Cheng, Z., Cai, X.-G., & Wang, H. (2015) · Journal of Investigative Medicine · doi:10.1097/jim.0000000000000201 · Cited by 8
“Peroxisome proliferation–activated receptor γ is a member of the nuclear hormone receptor superfamily and positively regulates cholesterol efflux in macrophages by increasing the expression of SR-BI/CLA-1 and ABCA1.”
BackgroundShen, J., Wei, W., Wang, X., Yang, J., Lu, L., Lv, X., & Xue, X. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/7275246 · Cited by 8
Schwing, W. D., Hustak, L. K., & Taylor, H. C. (2010) · Endocrine Practice · doi:10.4158/ep09307.or · Cited by 8
Xie, P., Zeng, X., Xiao, J., Sun, B., & Yang, D. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.08.014 · Cited by 8
Li, Y., Xu, Y., Li, X., Qin, Y., & Hu, R. (2013) · Molecular Medicine Reports · doi:10.3892/mmr.2013.1483 · Cited by 9
Colin, S., Chinetti, G., Kuivenhoven, J. A., & Staels, B. (2014) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-09665-0_20 · Cited by 8
“In addition to these hepatic effects, PPARα activation enhances reverse cholesterol transport related to the increase of ATP-binding cassette transporter A1 (ABCA1) in macrophages (Chinetti et al. 2001) and exerts many pleiotropic effects on vascular remodelling and inflammatory responses.”
BackgroundSelf-citationSeely, E. W., & Grinspoon, S. K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802101-9.00002-8 · Cited by 11
Rather, R. A., Malik, V. S., Trikha, D., Bhat, O. M., & Dhawan, V. (2016) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201500114 · Cited by 8
“Consistent with these results, PPAR- and LXRagonists are shown to inhibit macrophage-foam cell formation and positively control cholesterol efflux in macrophages by enhancing the expression of ABCA1, a transporter that controls cholesterol efflux from macrophages [63].”
ResultOsada, M., Sakai, T., Kuroyanagi, K., Kohno, H., & Tsuneoka, H. (2014) · PubMed Central · Cited by 8
Molavi, B., Rasouli, N., & Mehta, J. L. (2002) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840200700i101 · Cited by 9
Antiatherogenic Properties of Fibrates
Barter, P. J. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000168895.21726.20 · Cited by 8
Loeffler, D. A. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1368200 · Cited by 10
Optimized Method to Generate Well-Characterized Macrophages from Induced Pluripotent Stem Cells
Hai, Q., Bazeley, P. S., Han, J., Brubaker, G., Powers, J., Diaz-Montero, C. M., & Smith, J. D. (2025) · Biomedicines · doi:10.3390/biomedicines13010099 · Cited by 8
Cui, L., Ho, C. K., 梁盼红, Gao, W., Liu, J., Tian, X. Y., Wong, R. H. L., Zhou, B., & Lui, K. O. (2026) · Cardiovascular Research · doi:10.1093/cvr/cvag069 · Cited by 9
Lipid Metabolism in Tumor-Associated Myeloid-Derived Suppressor Cells
Liu, W., Song, H., Li, X., Ren, D., Ding, S., & Li, Y. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-33-6785-2_7 · Cited by 9
Effects of DNA methylation on cardiometabolic risk factors: a systematic review and meta-analysis
Barouti, Z., Heidari‐Beni, M., Shabanian-Boroujeni, A., Mohammadzadeh, M., Pahlevani, V., Poursafa, P., Mohebpour, F., & Kelishadi, R. (2022) · Archives of Public Health · doi:10.1186/s13690-022-00907-1 · Cited by 7
Wang, Y., Li, J., Hao, P., Li, J., Han, R., Lin, J., & Li, X. (2023) · Translational Vision Science & Technology · doi:10.1167/tvst.12.2.4 · Cited by 8
Akita, N., Tsujita, M., Yokota, T., Gonzalez, F. J., Ohte, N., Kimura, G., & Yokoyama, S. (2010) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.4820 · Cited by 7
Kasono, K., Nishida, J., Tamemoto, H., Fudaka, K., Namai, K., Kajio, H., Kuroki, M., Kanazawa, Y., & Kawakami, M. (2002) · Life Sciences · doi:10.1016/s0024-3205(02)01950-1 · Cited by 7
Saroglitazar, a novel cardiometabolic agent for diabetic dyslipidemia - A Review
Sharma, A. K., Amarnath, S., Kushwah, D. S., & Ramaswamy, S. (2014) · Journal of Young Pharmacists · doi:10.5530/jyp.2015.1.2 · Cited by 7
Application of Dunaliella in Atherosclerosis
Shaish, A., Horari, A., Kamari, Y., Cohen, H., Schonfeld, G., & Harats, D. (2019) · CRC Press eBooks · doi:10.1201/9780429061639-20 · Cited by 7
Metadata
- Authors
- Chinetti, G., Lestavel, S., Bocher, V., Remaley, A. T., Neve, B., Torra, I. P., Teissier, E., Minnich, A., Jaye, M., Duverger, N., Brewer, H. B., Fruchart, J.-C., Clavey, V., & Staels, B.
- Affiliations
- Inserm (FR)
- National Institutes of Health (US)
- Sanofi (France) (FR)
- Corresponding author
- Staels, Bart
- Venue
- Nature Medicine
- Published
- 2001-01
- Volume
- 7
- Issue
- 1
- Pages
- 53-58
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1524478189
- Cited by
- 1,170
- References
- 39
- Citations by year
- 2026: 12 · 2025: 29 · 2024: 31 · 2023: 41 · 2022: 25 · 2021: 28 · 2020: 30 · 2019: 20 · 2018: 29 · 2017: 31 · 2016: 38 · 2015: 33 · 2014: 50 · 2013: 37 · 2012: 38
- FWCI
- 99.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- PPARα, PPARγ, ABCA1, cholesterol efflux, foam cells, macrophages, reverse cholesterol transport, liver X receptor alpha, apolipoprotein A-I, Tangier disease, acetylated LDL, CD36, THP-1 macrophages
- MeSH terms
- Base Sequence, Biological Transport, Cells, Cultured, Cholesterol, Foam Cells, Humans, Transcription Factors, DNA Primers, Receptors, Cytoplasmic and Nuclear, ATP-Binding Cassette Transporters, ATP Binding Cassette Transporter 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.